Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SVR097
MIFTS: 68

Severe Cutaneous Adverse Reaction

Categories: Genetic diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Severe Cutaneous Adverse Reaction

About this section

MalaCards integrated aliases for Severe Cutaneous Adverse Reaction:

Name: Severe Cutaneous Adverse Reaction 57 38
Stevens-Johnson Syndrome 57 38 12 53 25 59 75 55 6 44 15 73
Toxic Epidermal Necrolysis 57 53 25 59 75 55 6 73
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum 53 25 73
Susceptibility to Severe Cutaneous Adverse Reaction 29 6 40
Drug-Induced Stevens Johnson Syndrome 53 25 73
Hypersensitivity Syndrome, Carbamazepine-Induced, Susceptibility to 57 13
Stevens-Johnson Syndrome/toxic Epidermal Necrolysis Spectrum 53 59
Stevens-Johnson Syndrome/toxic Epidermal Necrolysis 53 25
Dermatostomatitis, Stevens Johnson Type 53 59
Toxic Epidermolysis 53 59
Sjs-Ten 53 59
Sjs 53 75
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis 37
Stevens-Johnson Syndrome - Toxic Epidermal Necrolysis 53
Severe Cutaneous Adverse Reaction, Susceptibility to 57
Hypersensitivity Syndrome, Carbamazepine-Induced 57
Toxic Epidermal Necrolysis, Susceptibility to 57
Stevens-Johnson Syndrome, Susceptibility to 57
Mycoplasma-Induced Stevens Johnson Syndrome 25
Dermatostomatitis Stevens Johnson Type 75
Lyell's Syndrome 25
Lyell Syndrome 59
Sjs/ten 53
Ten 75

Characteristics:

Orphanet epidemiological data:

59
toxic epidermal necrolysis
Inheritance: Not applicable; Age of onset: All ages;
stevens-johnson syndrome
Inheritance: Not applicable; Age of onset: All ages;
stevens-johnson syndrome/toxic epidermal necrolysis spectrum
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare skin diseases


Sources

Summaries for Severe Cutaneous Adverse Reaction

About this section
NIH Rare Diseases : 53 Stevens-Johnson syndrome (SJS) is a very severe reaction that mainly affects the skin, mucous membranes, and eyes. It is often triggered by particular medications. This syndrome is an emergency medical condition that usually requires hospitalization and can be life-threatening. Symptoms may include fever and flu-like symptoms, followed by painful blistering of the skin and mucous membranes. SJS may also cause severe irritation to the eyes and damage to the cornea, which can lead to permanent eye damage and vision loss. SJS occurs twice as often in men than in women, and most cases occur in children and young adults under 30. However, it can develop in people of any age. Having certain variations of a gene called HLA-B increases the risk of developing SJS. Treatment focuses on eliminating the underlying cause, controlling symptoms, and minimizing complications. Treatment may involve standard therapies used for major burns, pain medications, and various eye treatments depending on the extent of eye involvement.

MalaCards based summary : Severe Cutaneous Adverse Reaction, also known as stevens-johnson syndrome, is related to schwartz-jampel syndrome, type 1 and sjogren syndrome. An important gene associated with Severe Cutaneous Adverse Reaction is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Allograft rejection. The drugs Ephedrine and Pseudoephedrine have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and liver, and related phenotypes are sudden cardiac death and dysphagia

Genetics Home Reference : 25 Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe skin reaction most often triggered by particular medications. Although Stevens-Johnson syndrome and toxic epidermal necrolysis were once thought to be separate conditions, they are now considered part of a continuum. Stevens-Johnson syndrome represents the less severe end of the disease spectrum, and toxic epidermal necrolysis represents the more severe end.

UniProtKB/Swiss-Prot : 75 Stevens-Johnson syndrome: A rare blistering mucocutaneous disease that share clinical and histopathologic features with toxic epidermal necrolysis. Both disorders are characterized by high fever, malaise, and a rapidly developing blistering exanthema of macules and target-like lesions accompanied by mucosal involvement. Stevens-Johnson syndrome is a milder disease characterized by destruction and detachment of the skin epithelium and mucous membranes involving less than 10% of the body surface area. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis and sometimes blindness. It can be caused by a severe adverse reaction to particular types of medication, although Mycoplasma infections may induce some cases.

Wikipedia : 76 Severe cutaneous adverse reactions or SCARs are a group of potentially lethal adverse drug reactions... more...

Description from OMIM: 608579
Sources

Related Diseases for Severe Cutaneous Adverse Reaction

About this section

Diseases related to Severe Cutaneous Adverse Reaction via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
# Related Disease Score Top Affiliating Genes
1 schwartz-jampel syndrome, type 1 12.1
2 sjogren syndrome 11.3
3 phenytoin or carbamazepine toxicity 10.9 HLA-A HLA-B
4 stevens-johnson syndrome/toxic epidermal necrolysis overlap syndrome 10.9
5 swyer-james syndrome 10.9
6 postherpetic neuralgia 10.9 HLA-A HLA-B
7 atrial tachyarrhythmia with short pr interval 10.8 HLA-A HLA-B
8 caplan's syndrome 10.8 FAS HLA-A
9 breast medullary carcinoma 10.8 FASLG GZMB
10 type ii mixed cryoglobulinemia 10.7 FAS FASLG
11 pars planitis 10.7 HLA-A HLA-B
12 lymphocytic gastritis 10.6 FAS FASLG GZMB
13 anterior uveitis 10.6 HLA-A HLA-B
14 lymphomatoid papulosis 10.6 FAS FASLG GZMB
15 alopecia areata 10.6 FASLG GZMB HLA-A
16 glaucomatocyclitic crisis 10.5 HLA-A HLA-B HLA-C
17 pityriasis rosea 10.5 HLA-A HLA-B HLA-C
18 human herpesvirus 8 10.5 HLA-A HLA-B HLA-C
19 idiopathic bronchiectasis 10.5 HLA-A HLA-B HLA-C
20 alveolar echinococcosis 10.5 HLA-A HLA-B HLA-C
21 hematopoietic stem cell transplantation 10.5 HLA-A HLA-B HLA-C
22 paraneoplastic pemphigus 10.5 HLA-A HLA-B HLA-C
23 spondyloarthropathy 10.4 HLA-A HLA-B HLA-C
24 acute myocarditis 10.4 FAS FASLG TLR3
25 aplastic anemia 10.3 FAS FASLG HLA-A HLA-B
26 vogt-koyanagi-harada disease 10.3 FAS HLA-A HLA-B TLR3
27 phenytoin toxicity 10.1 CYP2C19 CYP2C9
28 choriocarcinoma of the testis 10.1 FASLG GZMB
29 esophageal candidiasis 10.1 CYP2C19 CYP2C9
30 geographic tongue 10.0 EPHX1 HLA-A HLA-B HLA-C
31 behcet syndrome 10.0 FAS HLA-A HLA-B HLA-C HSPG2
32 burns 10.0
33 hemophagocytic lymphohistiocytosis 9.9 FAS GNLY GZMB
34 bipolar disorder 9.8
35 skin disease 9.8
36 bullous skin disease 9.8
37 graft-versus-host disease 9.8 FAS FASLG GZMB HLA-A HLA-B HLA-C
38 diabetes mellitus 9.8 FAS FASLG GZMB HLA-A HLA-B
39 human immunodeficiency virus type 1 9.7 HLA-A HLA-B HLA-C TLR3
40 epilepsy 9.7
41 acute generalized exanthematous pustulosis 9.7
42 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.7
43 multiple chemical sensitivity 9.7 CYP2C19 CYP2C9
44 epidermolysis bullosa acquisita 9.7

Graphical network of the top 20 diseases related to Severe Cutaneous Adverse Reaction:



Diseases related to Severe Cutaneous Adverse Reaction
Sources

Symptoms & Phenotypes for Severe Cutaneous Adverse Reaction

About this section

Clinical features from OMIM:

608579

Human phenotypes related to Severe Cutaneous Adverse Reaction:

59 32 (show all 48)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 sudden cardiac death 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001645
2 dysphagia 59 32 frequent (33%) Very frequent (99-80%),Frequent (79-30%) HP:0002015
3 nausea and vomiting 59 32 hallmark (90%) Occasional (29-5%),Very frequent (99-80%) HP:0002017
4 recurrent respiratory infections 59 32 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0002205
5 malabsorption 59 32 frequent (33%) Frequent (79-30%) HP:0002024
6 visual impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0000505
7 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000083
8 photophobia 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000613
9 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
10 polydipsia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001959
11 fatigue 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0012378
12 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
13 anemia 59 32 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0001903
14 myocardial infarction 59 32 occasional (7.5%) Occasional (29-5%) HP:0001658
15 abdominal pain 59 32 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0002027
16 abnormal blistering of the skin 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0008066
17 weight loss 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0001824
18 respiratory distress 59 32 occasional (7.5%) Occasional (29-5%) HP:0002098
19 corneal erosion 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0200020
20 abnormality of the pleura 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002103
21 elevated hepatic transaminases 59 32 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0002910
22 thrombocytopenia 59 32 occasional (7.5%) Very frequent (99-80%),Occasional (29-5%) HP:0001873
23 skin ulcer 59 32 occasional (7.5%) Occasional (29-5%) HP:0200042
24 pancreatitis 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001733
25 abnormal myocardium morphology 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001637
26 visual loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0000572
27 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002239
28 diarrhea 59 32 hallmark (90%) Very frequent (99-80%) HP:0002014
29 erythema 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0010783
30 macule 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0012733
31 conjunctivitis 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000509
32 neutropenia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001875
33 sepsis 59 32 occasional (7.5%) Very frequent (99-80%),Occasional (29-5%) HP:0100806
34 cough 59 32 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0012735
35 acute hepatic failure 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0006554
36 tracheoesophageal fistula 59 32 occasional (7.5%) Occasional (29-5%) HP:0002575
37 abnormality of neutrophils 59 32 frequent (33%) Frequent (79-30%) HP:0001874
38 abnormality of the urethra 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000795
39 abnormality of the vagina 59 32 occasional (7.5%) Occasional (29-5%) HP:0000142
40 dyspareunia 59 32 occasional (7.5%) Occasional (29-5%) HP:0030016
41 dysuria 59 32 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0100518
42 excessive salivation 59 32 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0003781
43 restrictive ventilatory defect 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002091
44 acantholysis 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0100792
45 entropion 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000621
46 intestinal perforation 59 32 occasional (7.5%) Occasional (29-5%) HP:0031368
47 esophageal stricture 59 32 occasional (7.5%) Occasional (29-5%) HP:0002043
48 hypokalemic metabolic alkalosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001960

GenomeRNAi Phenotypes related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.14 HLA-C HLA-B HLA-A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.14 HLA-C HLA-B HLA-A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.14 HLA-C HLA-B HLA-A
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.14 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.14 HLA-C
6 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.14 HLA-C HLA-B HLA-A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.14 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.14 HLA-B HLA-C HLA-A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.14 HLA-C HLA-B HLA-A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.14 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.14 HLA-C HLA-B HLA-A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.14 HLA-C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.14 HLA-C HLA-B HLA-A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.14 HLA-C HLA-B HLA-A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.14 HLA-C
16 Decreased hepcidin::fluc mRNA expression GR00253-A 9.56 NFKBIZ PTGER3 TGM1 TLR3 CYP2C19 FASLG
Sources

Drugs & Therapeutics for Severe Cutaneous Adverse Reaction

About this section

Drugs for Severe Cutaneous Adverse Reaction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ephedrine Approved Phase 4,Phase 1,Phase 2 299-42-3 9294
2
Pseudoephedrine Approved Phase 4,Phase 1,Phase 2 90-82-4 7028
3
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
4
Nevirapine Approved Phase 4 129618-40-2 4463
5
Pantoprazole Approved Phase 4 102625-70-7 4679
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3 22916-47-8 4189
7
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
8
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
9
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
10
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 59-30-3 6037
12 Respiratory System Agents Phase 4,Phase 1,Phase 2
13 Nasal Decongestants Phase 4,Phase 1,Phase 2
14 Tetrahydrozoline Phase 4,Phase 1,Phase 2
15 Ophthalmic Solutions Phase 4,Phase 1,Phase 2
16 Vasoconstrictor Agents Phase 4,Phase 1,Phase 2
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
19 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
20 Renal Agents Phase 4
21 Reverse Transcriptase Inhibitors Phase 4
22 Folic Acid Antagonists Phase 4
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Cyclosporins Phase 4,Phase 3
25 Cytochrome P-450 CYP3A Inducers Phase 4
26 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
27 Nucleic Acid Synthesis Inhibitors Phase 4
28 Vaccines Phase 4,Phase 3
29 Antacids Phase 4
30 Vitamin B Complex Phase 4,Phase 1,Phase 2
31 Immunosuppressive Agents Phase 4,Phase 3,Not Applicable
32 Fanasil, pyrimethamine drug combination Phase 4
33 Anti-Infective Agents Phase 4,Phase 3
34 Antifungal Agents Phase 4,Phase 3
35 Anti-HIV Agents Phase 4
36 Antiparasitic Agents Phase 4
37 Antiprotozoal Agents Phase 4
38 Proton Pump Inhibitors Phase 4
39 Anti-Retroviral Agents Phase 4
40 Antimalarials Phase 4
41 Anti-Ulcer Agents Phase 4
42 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
43 Antiviral Agents Phase 4
44 Calcineurin Inhibitors Phase 4,Phase 3
45 Folate Nutraceutical Phase 4,Phase 1,Phase 2
46 Vitamin B9 Nutraceutical Phase 4,Phase 1,Phase 2
47
Zinc Approved, Investigational Phase 3 7440-66-6 23994
48
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
49
Lamotrigine Approved, Investigational Phase 3,Phase 2 84057-84-1 3878
50
Etanercept Approved, Investigational Phase 3,Not Applicable 185243-69-0

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
2 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
3 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults Completed NCT01427309 Phase 4
4 IPT of Malaria With SP in Different Zones of Drug Resistance in Rwanda Completed NCT00372632 Phase 4 Sulfadoxine-Pyrimethamine;placebo
5 Stress Ulcer Prophylaxis in the Intensive Care Unit Completed NCT02467621 Phase 4 Pantoprazole
6 G-CSF in the Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
7 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM Completed NCT00736099 Phase 3 linagliptine 5 mg;linagliptine 5 mg and pioglitazone 30 mg
8 A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Completed NCT01621178 Phase 3 Dulaglutide;Insulin glargine;Insulin lispro
9 Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
10 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Completed NCT00346450 Phase 3
11 Clinical Evaluation of BW430C in Epilepsy Completed NCT00395694 Phase 3 lamictal
12 Aloe Vera on Irradiated Breast Tissue Completed NCT01824134 Phase 3
13 Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide Recruiting NCT03298802 Phase 3 Hydrochlorothiazide 50mg Tablet;Placebo Tablet
14 Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 cyclosporin A;Etanercept 50 MG Solution for Injection;Placebos
15 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Not yet recruiting NCT03486873 Phase 3 Standard of Care (SOC)
16 Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Terminated NCT00858364 Phase 3 Darbepoetin alfa;Placebo
17 Lamictal in the Treatment of Post-Herpetic Neuralgia Terminated NCT00295776 Phase 2, Phase 3 Lamictal in the treatment of Post-Herpetic Neuralgia
18 Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older Terminated NCT00976027 Phase 3
19 Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris Terminated NCT02613910 Phase 3 Ofatumumab;Acetaminophen/paracetamol;Antihistamine (cetirizine or equivalent);Prednisone/Prednisolone
20 Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell Deficiency Unknown status NCT00845117 Phase 1, Phase 2
21 Utilization of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Healing Completed NCT02746848 Phase 1, Phase 2
22 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
23 Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial Recruiting NCT02318485 Phase 2
24 Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Recruiting NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
25 Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study Recruiting NCT02229123 Phase 2 Intravenous Levetiracetam
26 Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
27 Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
28 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
29 Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
30 Topical Infliximab for Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
31 Severe Cutaneous Adverse Reactions in Thailand Unknown status NCT02574988
32 Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
33 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions Completed NCT01276314 Not Applicable anti- TNF-a;Prednisolone
34 Stevens-Johnson Syndrome Antimicrobial Completed NCT00844038
35 Salivary Gland Transplantation in the Treatment of Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242 Not Applicable
36 Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Completed NCT02945176 Not Applicable
37 Comparative Effectiveness of Intravenous v. Oral Antibiotic Therapy for Serious Bacterial Infections Completed NCT02311452
38 Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments Completed NCT01086319
39 Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268) Completed NCT01078246
40 Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration Completed NCT00460408 Macugen
41 HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Recruiting NCT03046914 Not Applicable
42 Drug Patch Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs) Recruiting NCT03176342 Not Applicable
43 An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate Recruiting NCT02520557
44 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Recruiting NCT02795143 Not Applicable Isotretinoin
45 Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Available NCT02149732
46 Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases Enrolling by invitation NCT00357071
47 HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions Not yet recruiting NCT03184597 Not Applicable
48 Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction. Not yet recruiting NCT03166241 Not Applicable
49 Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice Terminated NCT02989649 Alogliptin;Alogliptin FDC With Pioglitazone;Alogliptin FDC With Metformin

Search NIH Clinical Center for Severe Cutaneous Adverse Reaction

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Severe Cutaneous Adverse Reaction cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Severe Cutaneous Adverse Reaction:
Cultivated corneal epithelial stem cells for treatment of ocular surface damage
Embryonic/Adult Cultured Cells Related to Severe Cutaneous Adverse Reaction:
Limbal corneal epithelial stem cells PMIDs: 23055668

Cochrane evidence based reviews: stevens-johnson syndrome

Sources

Genetic Tests for Severe Cutaneous Adverse Reaction

About this section

Genetic tests related to Severe Cutaneous Adverse Reaction:

# Genetic test Affiliating Genes
1 Susceptibility to Severe Cutaneous Adverse Reaction 29 HLA-A HLA-B
Sources

Anatomical Context for Severe Cutaneous Adverse Reaction

About this section

MalaCards organs/tissues related to Severe Cutaneous Adverse Reaction:

41
Skin, Eye, Liver, T Cells, Testes, Neutrophil, Salivary Gland
Sources

Publications for Severe Cutaneous Adverse Reaction

About this section

Articles related to Severe Cutaneous Adverse Reaction:

(show top 50) (show all 677)
# Title Authors Year
1
Corneal Ectasia in Steven Johnson Syndrome: A Sequelae of Chronic Disease. ( 29890163 )
2018
2
Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome. ( 29528923 )
2018
3
Autoimmune Progesterone Dermatitis Mistaken for Stevens-Johnson Syndrome. ( 29528935 )
2018
4
Acute generalized exanthematous pustulosis simulating Stevens-Johnson syndrome/toxic epidermal necrolysis associated with the use of vismodegib. ( 29387760 )
2018
5
Severe Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome-beyond skin involvement. ( 29159901 )
2018
6
First case of Stevens-Johnson syndrome after rabies vaccination. ( 29333656 )
2018
7
Ocular surface cytokine profile in chronic Stevens-Johnson syndrome and its response to mucous membrane grafting for lid margin keratinisation. ( 28689166 )
2018
8
The association of HLA B*15:02 allele and Stevens-Johnson syndrome/toxic epidermal necrolysis induced by aromatic anticonvulsant drugs in a South Indian population. ( 29076187 )
2018
9
Stevens-Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database. ( 29387340 )
2018
10
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Treatment With a Biologic: A Case Report. ( 28488978 )
2017
11
Human Leukocyte Antigen Class I Genes Associated With Stevens-Johnson Syndrome and Severe Ocular Complications Following Use of Cold Medicine in a Brazilian Population. ( 28278336 )
2017
12
Genetics and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: What Have We Learned? ( 28278317 )
2017
13
Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome. ( 28885418 )
2017
14
Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study. ( 28366923 )
2017
15
Genome-wide association study using the ethnicity-specific Japonica array: identification of new susceptibility loci for cold medicine-related Stevens-Johnson syndrome with severe ocular complications. ( 28100913 )
2017
16
Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype. ( 29053440 )
2017
17
Association of Human Leukocyte Antigen Class 1 genes with Stevens Johnson Syndrome with severe ocular complications in an Indian population. ( 29162886 )
2017
18
Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens-Johnson syndrome. ( 29256167 )
2017
19
What's beneath the surface? Stevens-Johnson syndrome/toxic epidermal necrolysis combined with haemophagocytic lymphohistiocytosis: a case report. ( 28072947 )
2017
20
Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center. ( 27717620 )
2017
21
Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. ( 28144971 )
2017
22
A slowly developed severe cutaneous adverse reaction to idelalisib. ( 29150880 )
2017
23
Stevens Johnson Syndrome versus Jarisch Herxheimer Reaction in an HIV Positive Patient with Secondary Syphilis. ( 29076438 )
2017
24
Letter to the Editor concerning the article "Long term complications of Stevens-Johnson syndrome/Toxic epidermal necrolysis: The spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multi-disciplinary follow up. ( 28626892 )
2017
25
Drug-induced Stevens-Johnson syndrome in Indian population: A multicentric retrospective analysis. ( 28891542 )
2017
26
"Microbiological findings and antibacterial therapy in Stevens-Johnson syndrome/Toxic Epidermal Necrolysis patients from a Swedish Burn Center". ( 28075032 )
2017
27
Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study. ( 28499410 )
2017
28
Piperacillin-tazobactam-induced linear IgA bullous dermatosis presenting clinically as Stevens-Johnson syndrome/toxic epidermal necrolysis overlap. ( 28084616 )
2017
29
Serum IL-17 in patients with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis drug reaction, and correlation with disease severity. ( 28940568 )
2017
30
Are Idiopathic Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? The Example of Phenylbutazone. ( 28108296 )
2017
31
Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. ( 26927288 )
2017
32
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Induced by Fexofenadine. ( 28570227 )
2017
33
In vivo reflectance confocal microscopy of erythema multiforme and Stevens-Johnson syndrome: a histopathological correlation based on a case series. ( 28485871 )
2017
34
Cicatrizing Conjunctivitis in a Patient Diagnosed With Drug Reaction With Eosinophilia and Systemic Symptoms/Drug-Induced Hypersensitivity Syndrome but With Features of Stevens-Johnson Syndrome. ( 27078005 )
2016
35
Plasma Lipid Profiling of Patients with Chronic Ocular Complications Caused by Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. ( 27898730 )
2016
36
Coupling Genotyping and Computational Modeling in Prediction of Anti-epileptic Drugs that cause Stevens Johnson Syndrome and Toxic Epidermal Necrolysis for Carrier of HLA-B*15:02. ( 27096699 )
2016
37
Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease. ( 26882981 )
2016
38
Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. ( 26928377 )
2016
39
An Intractable Case of Prototheca Keratitis and Chronic Endophthalmitis in Stevens-Johnson Syndrome With Boston Type 1 Keratoprosthesis. ( 27442317 )
2016
40
Streptococcus agalactiae Endophthalmitis in Boston Keratoprosthesis in a Patient with Steven-Johnson Syndrome. ( 27994401 )
2016
41
Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. ( 27679410 )
2016
42
Rapidly Progressing Severe Cutaneous Adverse Reaction With Acute Kidney Injury After Drug Exposure: An Uncommon Presentation. ( 24832386 )
2016
43
Carbamazepine and oxcarbazepine: reflections after an oxcarbazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap. ( 27130345 )
2016
44
Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. ( 28011147 )
2016
45
Stevens-Johnson syndrome/toxic epidermal necrolysis caused by cefadroxil in a cat. ( 28491426 )
2016
46
UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermalA necrolysis in adults 2016 (print summary - Full guidelines available at http://dx.doi.org/10.1016/j.bjps.2016.01.034). ( 27216885 )
2016
47
A retrospective analysis of Stevens-Johnson syndrome/toxic epidermal necrolysis treated with corticosteroids. ( 27652522 )
2016
48
Spontaneous complete regression of hypothalamic pilocytic astrocytoma after partial resection in a child, complicated with Stevens-Johnson syndrome: a case report and literature review. ( 26662551 )
2016
49
U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. ( 27317286 )
2016
50
UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. ( 27287213 )
2016
Sources

Variations for Severe Cutaneous Adverse Reaction

About this section

ClinVar genetic disease variations for Severe Cutaneous Adverse Reaction:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HLA-B HLA-B*15: 02 undetermined variant risk factor
2 HLA-B HLA-B, HLA-B*5801 undetermined variant risk factor
3 HLA-A NM_001242758.1(HLA-A): c.776delC (p.Pro259Leufs) deletion not provided GRCh38 Chromosome 6, 29944278: 29944278
Sources

Expression for Severe Cutaneous Adverse Reaction

About this section
Search GEO for disease gene expression data for Severe Cutaneous Adverse Reaction.
Sources

Pathways for Severe Cutaneous Adverse Reaction

About this section

Pathways related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 37
Show member pathways
 12.71 FAS FASLG HLA-A HLA-B HLA-C TLR3
2
Allograft rejection 1 37
Show member pathways
 12.54 FAS FASLG GNLY GZMB HLA-A HLA-B
3
Influenza A 37
Show member pathways
 12.53 FAS FASLG HLA-A HLA-B HLA-C TLR3
4
NF-kappaB Signaling 4
12.15 FAS FASLG GZMB IKZF1 NFKBIZ TLR3
5
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 11.91 FAS FASLG GZMB HLA-A HLA-B HLA-C
6
IL12-mediated signaling events 1
Show member pathways
 11.71 FASLG GZMB HLA-A
7
Kaposi's sarcoma-associated herpesvirus infection 37
Show member pathways
 11.69 FAS FASLG HLA-A HLA-B HLA-C HSPG2
8
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.42 FASLG GZMB HLA-A
9
Phenytoin Pathway, Pharmacokinetics 61
Show member pathways
 11.36 CYP2C19 CYP2C9 EPHX1
10
Antigen Presentation- Folding, assembly and peptide loading of class I MHC 66
10.9 HLA-A HLA-B HLA-C
Sources

GO Terms for Severe Cutaneous Adverse Reaction

About this section

Cellular components related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.98 CYP2C19 CYP2C9 EPHX1 HLA-A HLA-B HLA-C
2 cell surface GO:0009986 9.63 FAS FASLG HLA-A HLA-B HLA-C TLR3
3 organelle membrane GO:0031090 9.58 CYP2C19 CYP2C9 EPHX1
4 recycling endosome membrane GO:0055038 9.54 HLA-A HLA-B HLA-C
5 phagocytic vesicle membrane GO:0030670 9.5 HLA-A HLA-B HLA-C
6 ER to Golgi transport vesicle membrane GO:0012507 9.43 HLA-A HLA-B HLA-C
7 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-A HLA-B HLA-C
8 MHC class I protein complex GO:0042612 8.8 HLA-A HLA-B HLA-C

Biological processes related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.93 FAS FASLG HLA-A HLA-B HLA-C
2 inflammatory response GO:0006954 9.83 FAS HSPG2 NFKBIZ PTGER3 TLR3
3 xenobiotic metabolic process GO:0006805 9.73 CYP2C19 CYP2C9 EPHX1
4 apoptotic signaling pathway GO:0097190 9.7 FAS FASLG TLR3
5 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.69 HLA-A HLA-B HLA-C
6 interferon-gamma-mediated signaling pathway GO:0060333 9.65 HLA-A HLA-B HLA-C
7 type I interferon signaling pathway GO:0060337 9.63 HLA-A HLA-B HLA-C
8 organic acid metabolic process GO:0006082 9.59 CYP2C19 CYP2C9
9 epoxygenase P450 pathway GO:0019373 9.58 CYP2C19 CYP2C9
10 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.58 FAS FASLG
11 necroptotic process GO:0070266 9.57 FASLG TLR3
12 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.55 FAS FASLG
13 extrinsic apoptotic signaling pathway GO:0097191 9.5 FAS FASLG TLR3
14 omega-hydroxylase P450 pathway GO:0097267 9.49 CYP2C19 CYP2C9
15 antigen processing and presentation GO:0019882 9.43 HLA-A HLA-B HLA-C
16 monoterpenoid metabolic process GO:0016098 9.4 CYP2C19 CYP2C9
17 protection from natural killer cell mediated cytotoxicity GO:0042270 9.37 HLA-A HLA-B
18 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.33 HLA-A HLA-B HLA-C
19 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.13 HLA-A HLA-B HLA-C
20 necroptotic signaling pathway GO:0097527 8.8 FAS FASLG TLR3

Molecular functions related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 arachidonic acid epoxygenase activity GO:0008392 8.96 CYP2C19 CYP2C9
2 peptide antigen binding GO:0042605 8.8 HLA-A HLA-B HLA-C
Sources

Sources for Severe Cutaneous Adverse Reaction

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....